Ziegler T R
Department of Medicine, Brigham and Women's Hospital, Boston, MA.
New Horiz. 1994 May;2(2):244-56.
Studies over the past three decades have documented the protein-anabolic effects of human growth hormone (GH) administration in malnourished or critically ill patients. The availability of recombinant GH has facilitated clinical investigation on the metabolic and clinical effects of this peptide in ICU settings. These studies demonstrate that GH improves nutrient utilization efficiency in critically ill patients. Recent randomized, controlled trials document improved wound healing with GH therapy in both adult and pediatric burn patients and reduced length of hospital stay in pediatric burn injury. However, little data have been published on functional or clinical outcome variables in other groups of catabolic patients treated with GH. Administration of growth factors in combination with specialized nutrition represents a novel strategy that may improve outcomes in critically ill patients. Additional clinical studies are needed to further define the safety, functional benefits, cost-effectiveness, and clinical utility of GH use in catabolic patients.
过去三十年的研究记录了在营养不良或重症患者中使用人生长激素（GH）的蛋白质合成代谢作用。重组GH的可得性促进了在重症监护病房环境中对这种肽的代谢和临床作用的临床研究。这些研究表明，GH可提高重症患者的营养利用效率。最近的随机对照试验证明，GH治疗可改善成人和儿童烧伤患者的伤口愈合情况，并缩短儿童烧伤患者的住院时间。然而，关于接受GH治疗的其他分解代谢患者群体的功能或临床结局变量的 published 数据很少。将生长因子与特殊营养相结合使用是一种可能改善重症患者结局的新策略。需要进一步的临床研究来进一步确定在分解代谢患者中使用GH的安全性、功能益处、成本效益和临床效用。
